n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)
Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting

Santarus And Pharming Announce RHUCIN Poster At American Academy Of Allergy, Asthma & Immunology 2011 Annual Meeting

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced new data on 62 patients with Hereditary Angioedema (HAE) who received repeat...

Santarus Initiates Phase I Clinical Study With SAN-300

Santarus Initiates Phase I Clinical Study With SAN-300

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

Santarus Inc. Stock Downgraded (SNTS)

Santarus Inc. Stock Downgraded (SNTS)

Santarus (Nasdaq:SNTS) has been downgraded by TheStreet Ratings from from a hold to sell.

SuperGen - Upgrades & Downgrades

SuperGen - Upgrades & Downgrades

TheStreet Ratings released rating changes on 21 U.S. common stocks for March 3, 2011. 12 stocks were upgraded and nine stocks were downgraded by our stock model.

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Management Discusses Q4 2010 Results - Earnings Call Transcript

Santarus Reports Fourth Quarter And Full Year 2010 Financial Results

Santarus Reports Fourth Quarter And Full Year 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter and full year ended December 31, 2010.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Pharming Announce Receipt Of FDA Refusal To File Letter For RHUCIN Biologics License Application

Santarus And Pharming Announce Receipt Of FDA Refusal To File Letter For RHUCIN Biologics License Application

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS) and biotech company Pharming Group NV (NYSE Euronext:PHARM) today announced the receipt of a “refusal to file” letter from the U.

Santarus To Hold Fourth Quarter And Full Year 2010 Financial Results Conference Call On March 3

Santarus To Hold Fourth Quarter And Full Year 2010 Financial Results Conference Call On March 3

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release fourth quarter and full year 2010 financial results after market close on Thursday, March 3, 2011.

Santarus And Pharming Announce Initiation Of Phase IIIb Clinical Study With RHUCIN In Acute Hereditary Angioedema

Santarus And Pharming Announce Initiation Of Phase IIIb Clinical Study With RHUCIN In Acute Hereditary Angioedema

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, ...

Santarus To Present At The 13th Annual Bio CEO & Investor Conference

Santarus To Present At The 13th Annual Bio CEO & Investor Conference

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets

Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets

Santarus, Inc. (NASDAQ: SNTS) and Depomed, Inc.

Savient Pharmaceuticals: Premarket Trading

Savient Pharmaceuticals: Premarket Trading

Savient Pharmaceuticals president Paul Hamelin will continue to lead the company until it hires a new CEO.

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR Are Big Market Movers

Beazer, Sears, KBR, Rare Element Resources, Hecla are big market movers Tuesday

Santarus And Pharming Announce Submission Of RHUCIN Biologics License Application To FDA

Santarus And Pharming Announce Submission Of RHUCIN Biologics License Application To FDA

Specialty biopharmaceutical company Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced the submission of a Biologics License Application (BLA) to the U.

Santarus To Present At Piper Jaffray 22nd Annual Health Care Conference

Santarus To Present At Piper Jaffray 22nd Annual Health Care Conference

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Santarus Announces Commercial Launch Of Novel Type 2 Diabetes Drug CYCLOSET

Santarus Announces Commercial Launch Of Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the commercial U.

Santarus CEO Discusses Q3 2010 Results – Earnings Call Transcript

Santarus CEO Discusses Q3 2010 Results – Earnings Call Transcript

Santarus CEO Discusses Q3 2010 Results â¿¿ Earnings Call Transcript

Santarus Reports Third Quarter 2010 Financial Results

Santarus Reports Third Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2010.

Santarus Announces Positive Top-Line Results In E.U. Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis

Santarus Announces Positive Top-Line Results In E.U. Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced positive top-line results from a second Phase III clinical study evaluating the safety and efficacy of budesonide MMX ® for the...

Cycloset Data To Be Presented In Poster Session At 8th Annual World Congress On Insulin Resistance, Diabetes & CVD

Santarus, Inc. (NASDAQ:SNTS) and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET ® (bromocriptine mesylate) tablets...

Santarus To Hold Third Quarter 2010 Financial Results Conference Call On November 8

Santarus To Hold Third Quarter 2010 Financial Results Conference Call On November 8

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release third quarter 2010 financial results after market close on Monday, November 8, 2010.

RHUCIN Clinical Trial Data Published In The Journal Of Allergy And Clinical Immunology

RHUCIN Clinical Trial Data Published In The Journal Of Allergy And Clinical Immunology

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN ® (recombinant human...

Hypercom, YRC Worldwide: Volume Movers

Hypercom and YRC Worldwide were among stocks poised to move on above-average volume Thursday.

Santarus Adds Two Novel Biologic Drug Candidates To Pipeline

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, has expanded its development pipeline with the addition of two novel biologic drug candidates focused on specialty markets.

Santarus, Geron: Volume Movers

Several stocks trading below $5, including Santarus, were poised to move on above-average volume Thursday.

Santarus To Present At September Investment Conferences

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T.

Fuqi Down on SEC Probe; Symantec Steady

Shares of Fuqi International dropped in extended trades after the company said it's the subject of a formal probe by the SEC, while Symantec built on gains in the regular session.

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc.